14-3-3 Proteins Negatively Regulate Microglial Activation via Inhibition of the NF-κB Pathway

Area of Science:

• Neuroimmunology
• Cellular Biology
• Molecular Neuroscience

Background:

• Microglia are central nervous system (CNS) immune cells implicated in neurodegenerative diseases like Alzheimer's, Dementia with Lewy Bodies, and Parkinson's.
• 14-3-3 proteins are crucial regulators of cellular functions, including signaling and apoptosis, and have shown decreased levels in neurodegenerative disease brains.
• The precise role of 14-3-3 proteins in microglial inflammatory responses remains largely uncharacterized.

Purpose of the Study:

• To investigate the function of 14-3-3 proteins in the microglial inflammatory response.
• To determine the effect of 14-3-3 inhibition on microglial activation and associated pathways.
• To explore the potential of 14-3-3 proteins as therapeutic targets for CNS diseases.

Main Methods:

• Treatment of immortalized BV-2 and primary mouse microglia with lipopolysaccharide (LPS).
• Utilized 14-3-3 inhibitors (BV02 and difopein) to block 14-3-3 protein-protein interactions.
• Assessed microglial activation markers, phagocytosis, cytokine release, chemotaxis, and NF-κB pathway activation (including IKKβ and IκBα).

Main Results:

• LPS treatment increased 14-3-3 protein levels in microglia.
• Inhibition of 14-3-3 proteins significantly enhanced LPS-induced microglial activation, phagocytosis, lysosomal proteolysis, and cytokine release.
• 14-3-3 inhibition diminished chemotaxis and accelerated NF-κB pathway activation by disrupting the interaction between 14-3-3 and IKKβ, leading to increased IκBα degradation.

Conclusions:

• 14-3-3 proteins play a critical regulatory role in mitigating the inflammatory response of microglia.
• Disruption of 14-3-3 function potentiates microglial pro-inflammatory signaling.
• 14-3-3 proteins represent promising therapeutic targets for managing neuroinflammation in CNS diseases.